HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Symbollon expands Iogen distribution

This article was originally published in The Tan Sheet

Executive Summary

New England Vitamin Brokers will expand the presence of Symbollon Pharmaceuticals Inc.'s Iogen women's breast health supplement in New England. Medfield, Mass.-based Symbollon said June 16 it is exploring additional retail distribution channels for Iogen, which launched in February touting clinically proven effects in women with fibrocystic breast disease (1"The Tan Sheet" Feb. 22, 2010). NEVB Director Michael Goolkasian called Iogen "a truly unique product supported by extensive clinical data.

You may also be interested in...



New Products In Brief

Symbollon takes supplement route: IoGen launches as a dietary supplement for women's breast health after Symbollon Pharmaceuticals' application with FDA seeking medical food approval stalled, said a spokeswoman for the Medfield, Mass., biotech firm. Symbollon completed eight clinical trials evaluating the effects of its molecular iodine compound on mastalgia and fibrosis in more than 2,000 patients. Starting in February, IoGen will be available in health food stores, online and through gynecologists, at a suggested retail price of $29.99 for 30 tablets

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS134835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel